<DOC>
	<DOCNO>NCT02024633</DOCNO>
	<brief_summary>Research Hypothesis : icotinib administer combination gemcitabine acceptable safety profile subject locally advanced , unresectable metastatic pancreatic adenocarcinoma.The primary objective determine safety profile icotinib combination gemcitabine subject locally advanced , unresectable metastatic pancreatic adenocarcinoma .</brief_summary>
	<brief_title>Combination Icotinib Gemcitabine First-line Treatment Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Locally advanced , unresectable metastatic pancreatic cancer histologic cytologic confirmation without previous chemotherapy target therapy . ECOG Performance Status 0 1 . Adequate organ function define studyspecified laboratory test . Signed informed consent form . Willing able comply study procedure . Previous chemotherapy target therapy . Currently history certain studyspecified heart , liver , kidney , lung , neurological , immune medical condition . Systemically active steroid . Another investigational product within 28 day prior receive study drug . Major surgery significant traumatic injury ( unhealed surgical wound ) occur within 28 day prior receive study drug . Infection HIV , hepatitis B C screening . Pregnant lactating . Conditions , include alcohol drug dependence , intercurrent illness would affect patient 's ability comply study visit procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>